1. 37OSubgroup analysis of IMpassion130: Atezolizumab + nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries. (24th November 2019) Authors: Iwata, H; Im, S-A; Sohn, J; Jung, K H; Im, Y-H; Lee, K S; Inoue, K; Tamura, K; Wong, A; Emens, L A; Barrios, C H; Adams, S; Schneeweiss, A; Diéras, V; Winer, E P; Chui, S Y; Henschel, V; Rugo, H S; Loi, S; Schmid, P Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial. (23rd January 2019) Authors: Delaloge, S; Cella, D; Ye, Y; Buyse, M; Chan, A; Barrios, C H; Holmes, F A; Mansi, J; Iwata, H; Ejlertsen, B; Moy, B; Chia, S K L; Gnant, M; Smichkoska, S; Ciceniene, A; Martinez, N; Filipović, S; Ben-Baruch, N E; Joy, A A; Langkjer, S T Journal: Annals of oncology Issue: Volume 30:Number 4(2019) Page Start: 567 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. (29th January 2018) Authors: Knox, J J; Barrios, C H; Kim, T M; Cosgriff, T; Srimuninnimit, V; Pittman, K; Sabbatini, R; Rha, S Y; Flaig, T W; Page, R D; Beck, J T; Cheung, F; Yadav, S; Patel, P; Geoffrois, L; Niolat, J; Berkowitz, N; Marker, M; Chen, D; Motzer, R J Journal: Annals of oncology Issue: Volume 29:Number 11(2018) Page Start: 2269 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study. (15th December 2019) Authors: Herbst, R S; de Marinis, F; Giaccone, G; Reinmuth, N; Vergnenegre, A; Barrios, C H; Morise, M; Felip, E; Andric, Z; Geater, S; Ozguroglu, M; Mocci, S; McCleland, M; Zou, W; Enquist, I; Komatsubara, K; Deng, Y; Kuriki, H; Spigel, D R; Jassem, J Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. LBA1_PRIMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC). (23rd October 2018) Authors: Schmid, P; Adams, S; Rugo, H S; Schneeweiss, A; Barrios, C H; Iwata, H; Dieras, V; Hegg, R; Im, S-A; Wright, G S; Henschel, V; Molinero, L; Chui, S Y; Funke, R; Husain, A; Winer, E P; Loi, S; Emens, L A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗